Adaptive Biotechnologies Corporation Common Stock
ADPTAdaptive Biotechnologies Corporation focuses on immune-driven medicine and develops immune system-based diagnostics and therapeutics. It leverages its proprietary immune sequencing platform to understand and interpret the adaptive immune system, primarily through analyzing T-cell and B-cell receptors to improve disease detection and treatment. The company collaborates with various research and pharmaceutical organizations to advance immunotherapy and immune-based diagnostics.
Company News
Adaptive Biotechnologies presented 90 abstracts at the ASH Annual Meeting, highlighting its clonoSEQ® test's effectiveness in guiding treatment interventions across multiple blood cancer types, demonstrating precision in measurable residual disease (MRD) monitoring.
Adaptive Biotechnologies' stock dropped after Natera acquired Foresight Diagnostics for $275 million upfront, raising competitive concerns in the blood-cancer minimal residual disease (MRD) market.
Adaptive Biotechnologies reported strong Q2 2025 results with 36% revenue growth, primarily driven by minimal residual disease (MRD) business. The company beat analyst expectations and raised its MRD revenue guidance for 2025.
Agenus Inc. (AGEN) shares plunged 58.8% after the FDA discouraged the accelerated approval pathway for the company's immunotherapy combination botensilimab (BOT) and balstilimab (BAL) in relapsed/refractory microsatellite stable colorectal cancer. The FDA cited concerns that the observed objective response rate might not translate to a survival b...
